Retroperitoneal sarcomas: Combined-modality treatment approaches

Authors

  • Chandrajit P. Raut MD, MSc,

    1. Department of Surgery, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts
    Search for more papers by this author
  • Peter W.T. Pisters MD

    Corresponding author
    1. Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Department of Surgical Oncology, Unit 444, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030-4009. Fax: (713) 792-7829.
    Search for more papers by this author

Abstract

Retroperitoneal sarcomas (RPS) are rare tumors, accounting for approximately 15% of soft tissue sarcomas. Surgical resection of localized tumors with gross and microscopically negative margins remains the standard of care. However, because RPS are frequently large and locally advanced, resections are often incomplete, resulting in local recurrence. Investigators are evaluating combined-modality therapies to improve local control and disease-specific survival. This review outlines current concepts and evolving treatment strategies in the diagnosis, staging, and management of RPS. J. Surg. Oncol. 2006;94:81–87. © 2006 Wiley-Liss, Inc.

Ancillary